Swiss dermatology company Galderma Group AG’s flagship skin care brands Cetaphil and Alastin drove net sales of its Dermatological Skincare division up 10.6% year-on-year at constant currency rates in the first nine months to $990m. Cetaphil growth was “particularly strong” in non-US markets, more than offsetting lower consumer consumption in the US, while Alastin continued its US growth across channels, said the firm, with US headquarters in Dallas. Cetaphil is marketed in 90 countries. In the quarter, the firm invested behind Cetaphil’s growth “with a re-energized brand, focused retailer execution and a digital-first activation,” Galderma said. “This included placement in Walmart in the US with a multi-channel activation.” The company also launched Cetaphil Gentle Exfoliating line “to provide gentle chemical exfoliation that is suitable for daily use, even on the most sensitive skin.”
Cosmetics Industry Q3: Cetaphil Investments Drive Galderma Derm Division; Inflation Impacting Direct-To-Consumer Sales; More
Galderma Group AG’s investments in Cetaphil launch, ‘re-energizing’ of brand pay off with sales of the dermatology unit up 10.6% in the third quarter. Separately, Spanish beauty company Puig reports its Fragrance and Fashion business grew 11.1% and its makeup division advanced 7.3% in the quarter, while data insights company Consumer Edge identifies slowdown in direct-to-consumer beauty sales.
More from Earnings
More from HBW Insight
Kim Kardashian lifestyle company SKIMS buys back rights to SKKN by Kim from Coty, Inc., which had purchased a 20% interest in the brand in 2020 for $200m. Separately, NYX Professional Makeup partners with Warner Bros. to launch the “A Minecraft Movie” collection.
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
US FDA Commissioner nominee Martin Makary is being embraced by industry, and Senate Democrats, as a more traditional pick than other Trump Administration nominees, but the Make America Healthy Again agenda still is clearly coming to the agency.